Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.
ASCO Annual Meeting
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
Advertisement
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
Advertisement
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non –small cell lung cancer after Tagrisso.
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.
Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
